Consumer packaged goods stocks were one of the strongest groups for the first half of the year, as investors seeking income flocked to them for a bond market alternative.
In the past few weeks, the group has lost its luster partially because a rate hike from the Fed later this year could put a dent in the bond market alternatives, and also because of the strong dollar.
Clorox reported solid earnings on Wednesday that showed strong organic growth. Even though it ultimately showed a small bottom line miss, Cramer was thrilled by management's guidance for 2017.
To learn more about what could be ahead for the company, Cramer spoke with Clorox CEO Benno Dorer.
"One of the hallmarks of our company now is that we have growth where others don't. And the reason is pretty simple. We take out costs and we reinvest those cost savings into the business," Dorer said.
RR Donnelley & Sons is the world's largest commercial printing company was thrust into the spotlight last year when it announced plans to break itself up into three separate entities.
The goal of the break-up is to unlock further value as a multi-channel communications management business, a printing business for magazines and catalogs and a financial communications and data services company.
With chatter of a possible merger with Xerox, Cramer worried that it could put a hold on RR Donnelley's break-up plans. To make matters even more confusing, the company reported an earnings beat with higher than expected revenue, but its stock was hit because the full-year revenue forecast was at the low end of management's prior guidance.
To gain clarity, Cramer spoke with RR Donnelley's President and CEO Tom Quinlan, who assured investors that the break-up is on track.
"We haven't responded on rumors in the nine years that I have been CEO, and we are not going to start now. But what I will tell you is we are on track for the spins," Quinlan said.
In the Lightning Round, Cramer gave his take on a few caller favorite stocks:
Opko Health: "Phil Frost [CEO] I think he's doing his thing. Ever since that acquisition the stock has done nothing, it's flatlined. I'm still with Phil."
AbbVie: "The company is doing everything right. I urge you to stick with it. I think it's terrific. I wouldn't touch a thing. I want you to be in it."